BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/17/2016 12:43:00 PM | Browse: 997 | Download: 1535
 |
Received |
|
2015-09-29 08:59 |
 |
Peer-Review Started |
|
2015-10-02 15:23 |
 |
To Make the First Decision |
|
2015-10-27 11:31 |
 |
Return for Revision |
|
2015-11-04 16:01 |
 |
Revised |
|
2016-01-07 14:55 |
 |
Second Decision |
|
2016-02-16 10:20 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2016-03-09 12:42 |
 |
Articles in Press |
|
2016-03-09 12:42 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2016-03-17 09:19 |
 |
Typeset the Manuscript |
|
2016-05-06 11:45 |
 |
Publish the Manuscript Online |
|
2016-05-17 12:43 |
ISSN |
1948-9366 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Therapeutics Advances |
Article Title |
Targeted therapy of gastrointestinal stromal tumours
|
Manuscript Source |
Invited Manuscript |
All Author List |
Ashish Jakhetiya, Pankaj Kumar Garg, Gaurav Prakash, Jyoti Sharma, Rambha Pandey and Durgatosh Pandey |
Funding Agency and Grant Number |
|
Corresponding Author |
Dr. Pankaj Kumar Garg, Associate Professor, Department of Surgery, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Dilshad Garden, Delhi 110095,
India. dr.pankajgarg@gmail.com
|
Key Words |
Gastrointestinal tumors; Molecular targeted therapy; Protein kinase inhibitors; Imatinib; Survival |
Core Tip |
Gastrointestinal stromal tumors (GISTs) are common mesenchymal tumours of the gastrointestinal tract. They are characterized by the presence of a driver kinase-activating mutation in either CD-117 or platelet-derived growth factor receptor α. Development of tyrosine kinase inhibitors has led to a paradigm shift in the management of GISTs. Surgery is the primary modality of treatment in localized non-metastatic GISTs. Adjuvant Imatinib for three years is a preferred option for high-risk patients to lessen disease recurrence. The role of neoadjuvant Imatinib is evolving. Imatinib, Sunitinib, and Regorafinib are recommended as first, second and third-line targeted therapies, respectively, for the management of metastatic GISTs.
|
Publish Date |
2016-05-17 12:43 |
Citation |
Jakhetiya A, Garg PK, Prakash G, Sharma J, Pandey R, Pandey D. Targeted therapy of gastrointestinal stromal tumours. World J Gastrointest Surg 2016; 8(5): 345-352 |
URL |
http://www.wjgnet.com/1948-9366/full/v8/i5/345.htm |
DOI |
http://dx.doi.org/10.4240/wjgs.v8.i5.345 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345